Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study

Li J(Zhejiang Medicine (China)), Rongbo Lin(Fujian Provincial Cancer Hospital), Jian Xu(Chinese PLA General Hospital), Jianfeng Zhou(Tongji University), Jieer Ying(Zhejiang Cancer Hospital), Yi Ba(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoping Qian(Nanjing Drum Tower Hospital), Ying Cheng(First Hospital of China Medical University), Yali Shen(Sichuan University), Yanqiao Zhang(Harbin Medical University), Xiao Yan Ke(Chengdu Organic Chemicals (China)), Nong Xu(First Affiliated Hospital Zhejiang University), Rui Wu(Second Military Medical University), Jufeng Wang(Zhengzhou University)
Clinical Colorectal Cancer
November 10, 2024
10.1016/j.clcc.2024.10.003
Cited by 0

Related Papers

Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|944
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Comprehensive analysis of spatial architecture in primary liver cancer
|Science Advances|2021|359
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|291